We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Amgen Inc | NASDAQ:AMGN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 33.02 | 11.86% | 311.41 | 311.40 | 320.00 | 322.54 | 308.68 | 313.42 | 9,644,684 | 05:00:03 |
From May 2019 to May 2024
By Jared Hopkins
Some drugmakers are starting to limit in-person sales calls on doctors and their offices in response to the coronavirus outbreak.
Merck & Co., Amgen Inc. and Amarin Corp. PLC are among the companies that say they are temporarily halting salespeople from doing business face-to-face.
Pharmaceutical companies for decades have relied on sales representatives to "detail" doctors, nurses and others with pitches to boost prescriptions.
Merck confirmed its stand-down on Monday. Amarin, which sells heart drug Vascepa, said on Sunday it was suspending detailing until March 30. Biotech Amgen, which sells rheumatoid-arthritis drug Enbrel, said on Friday it was suspending the calls until April 17.
(END) Dow Jones Newswires
March 16, 2020 14:14 ET (18:14 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Amgen Chart |
1 Month Amgen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
